SPX3,825.33
1.06%Positive
IXIC11,127.84
0.90%Positive
DJI31,097.26
1.05%Positive
STOXX407.13
0.02%Negative
FTSE7,168.65
0.01%Negative
N22525,935.62
1.73%Negative

Vaccinex Inc

VCNX.OQ

Official Data Partner

Latest Trade: trading lower1.04USD
Change: -0.04
% Change: 3.70%Negative

Day Range

1.03 - 1.08

52-Week Range

0.90 - 2.83

Previous Close: 1.08
Open: 1.07
Volume: 3,933.00
3 Month Average Trading Volume: 2.19
Shares Out (Mil): 42.66
Market Cap: 46.08
Forward P/E: -99,999.99
Dividend Yield: -99,999.99

Key Statistics

mean rating - analysts

Sell

Hold

Buy

P/E Excl. Extra Items (TTM): -99,999.99
Price To Sales (TTM): 921.54
Price To Book (Quarterly): 2.85
Price To Cash Flow (Per Share TTM): -99,999.99
Total Debt/Total Equity (Quarterly): 1.42
Long Term Debt/Equity (Quarterly): 0.96
Return On Investment (TTM): -223.01
Return On Equity (TTM): -83.60

2021 (millions USD)

About Vaccinex Inc

Company Information

Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate, pepinemab (VX15/2503), is a humanized monoclonal antibody that binds and blocks the signaling activity of semaphorin 4D (SEMA4D). It is focused on the development of pepinemab for the treatment of certain cancer indications, in particular, head and neck squamous cell carcinoma (HNSCC) as well as neurodegenerative diseases, including Huntington's disease (HD), and Alzheimer's disease, (AD). The Company has discovered VX5 using its ActivMAb antibody discovery platform. VX5 is a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, and is in preclinical development for the treatment of multiple sclerosis (MS) and for other autoimmune disorders.